New Cycle Capital

New Cycle Capital is a California-based venture capital firm founded in 2007 by Josh Becker and Benjamin Black. The firm focuses on early-stage investments in capital-efficient businesses, often serving as the sole institutional investor alongside angel investors in their first round of funding. New Cycle Capital primarily targets companies in North America and has a diverse portfolio that includes businesses such as GOALSPRING, OPOWER, RENEWABLE FUNDING, SABEResPODER, TerraPass, and VILLA. The firm aims to support innovative companies that are well-positioned for growth and sustainability.

Josh Becker

General Partner and Co-founder

7 past transactions

Care Daily

Series A in 2014
Care Daily is an Internet of Things (IoT) software company that specializes in developing cloud-based solutions for smart home and smart building applications. Founded in 2009 and headquartered in Palo Alto, California, Care Daily offers a comprehensive suite of products designed to facilitate the connection, engagement, and management of IoT devices. Its offerings include the People Power Energy Service Platform, which transforms real-time data from energy-consuming devices into insightful reports, and various mobile applications that enhance user interaction with connected devices. Additionally, Care Daily provides tools such as open-source APIs for manufacturers to integrate their products and a command center for device management. The company's solutions cater to both residential and commercial users, enabling them to monitor and control their energy consumption effectively. Care Daily also focuses on remote senior care and family connectivity through its Presence Family Care Pack, alongside advanced services such as HVAC fault detection powered by artificial intelligence.

GoalSpring Financial

Series A in 2010
GoalSpring Financial, Inc. offers DebtGoal, an online application that enables users to organize, optimize, and pay their debt. It operates DebtGoals.Com, an online debt management service that takes into account customer's debt, such as credit cards, student loans, car loans, and mortgages, as well as enables them to organize, optimize, and pay-down their debt. GoalSpring Financial, Inc. was founded in 2008 and is based in San Francisco, California.

SavvyMoney

Series A in 2010
SavvyMoney is a venture funded, fintech company that provides integrated credit score and personal finance solutions to over 125 Credit Unions and Banks. SavvyMoney’s solution provides free credit score, report and daily monitoring. Its pre-qualification offer engine displays targeted financial offers from the financial service partner based on the user’s credit score. SavvyMoney is poised for significant growth in 2017-18. In addition to receiving a strategic investment from TransUnion(NYSE: TRU), SavvyMoney entered into a partnership with Fiserv (NASDAQ: FISV) to power its credit score solution, Credit Sense on 9 of their online banking platforms.

Renew Financial

Series A in 2009
Renew Financial specializes in providing innovative financing solutions aimed at supporting contractors in the renewable energy and energy efficiency sectors. Founded in 2008 by Cisco DeVries, the company focuses on promoting energy independence and transitioning to a clean energy economy. Its primary offerings include the Property Assessed Clean Energy (PACE) financing model and the Warehouse for Energy Efficiency Loans, which facilitate access to financing for residential energy efficiency projects by attracting institutional investors. Renew Financial's platform provides both secured and unsecured financing options to homeowners, contractors, and local governments, enabling them to undertake energy, safety, and water efficiency improvements. This approach not only helps property owners reduce energy consumption but also aids local governments in creating jobs and fostering sustainable development.

REGiMMUNE

Series B in 2008
REGiMMUNE Corporation is a biotechnology company focused on developing immune-regulatory therapeutics aimed at treating various life-threatening diseases and immune disorders. Founded in 2006 and headquartered in Tokyo, Japan, with an office in San Francisco, the company utilizes its proprietary reVax technology to induce regulatory T cells, fostering immune tolerance against specific disease-causing antigens. REGiMMUNE's therapeutic offerings include RGI-2001, currently in a Phase I/II clinical trial for treating Graft versus Host Disease associated with hematopoietic stem cell transplantation, and RGI-1000 for allergy management. The company is also developing RGI-3100 series for type 1 diabetes and other products aimed at preventing inhibitor formation in enzyme replacement therapies and treating inflammatory bowel disease. Their innovative approach seeks to minimize the side effects associated with conventional immunosuppressants while providing effective long-term solutions for conditions such as rheumatoid arthritis and multiple sclerosis.

Opower

Series A in 2007
Opower, Inc. is a leading provider of cloud-based software solutions for the utility industry, focused on enhancing customer engagement and promoting energy efficiency. The company collaborates with over 85 utility partners, serving more than 18 million consumers across seven countries. Its software analyzes energy usage data and delivers personalized insights to motivate consumers to reduce their energy consumption. Opower's offerings include home energy reports, smart meter-enabled communications, and a marketplace suite for product recommendations. Additionally, the company provides demand response solutions, such as alerts and feedback reports to encourage reduced energy use during peak times. Opower also enhances digital engagement through customer-facing web applications and tools aimed at improving customer satisfaction. Founded in 2007 and headquartered in Arlington, Virginia, Opower operates as a subsidiary of Oracle Corporation.

REGiMMUNE

Series A in 2007
REGiMMUNE Corporation is a biotechnology company focused on developing immune-regulatory therapeutics aimed at treating various life-threatening diseases and immune disorders. Founded in 2006 and headquartered in Tokyo, Japan, with an office in San Francisco, the company utilizes its proprietary reVax technology to induce regulatory T cells, fostering immune tolerance against specific disease-causing antigens. REGiMMUNE's therapeutic offerings include RGI-2001, currently in a Phase I/II clinical trial for treating Graft versus Host Disease associated with hematopoietic stem cell transplantation, and RGI-1000 for allergy management. The company is also developing RGI-3100 series for type 1 diabetes and other products aimed at preventing inhibitor formation in enzyme replacement therapies and treating inflammatory bowel disease. Their innovative approach seeks to minimize the side effects associated with conventional immunosuppressants while providing effective long-term solutions for conditions such as rheumatoid arthritis and multiple sclerosis.